Anticoagulants

By: Sami Barghshoon, BioFiles v7 n5, 2012, 25–26

BioFiles Volume 7, Number 5 – Pharmaceutical Drugs and Drug Candidates

Download BioFiles v7 n5 (3.18 Mb PDF)
Back to Pharmaceutical Drugs and Drug Candidates homepage

Browse the Anticoagulants product list

Pulmonary arterial hypertension (PAH) is characterized as a progressive, incurable disease and its treatment remains elusive.1 The mean survival rate is often less than 4 years and the median survival period is 2.8 years.2

In the 1980s, one treatment of PAH focused on anticoagulant therapy. Fuster et al. reported a statistically significant improvement in the survival of patients who had been treated with warfarin compared to patients who had received no anticoagulants.3 Rich et al. found the use of anticoagulants may benefit patients with PAH who do not respond to therapy with calcium-channel blockers.4

Novel approaches to treat PAH include Rho-kinase inhibitors and soluble guanylate cyclase stimulators.5 Animal models have shown these new classes of agents mitigate the abnormal pulmonary vasoconstriction associated with the disease.

Sigma® Life Science is the source for all five approved anticoagulants listed below. Sigma Life Science also offers the drug candidate GSK-429286 (Cat. No. SML0231), a ROCK1 inhibitor from GSK, the approved drug Sildenafil (Cat. No. PZ0003), a guanylate cyclase activator from Pfizer, and the powerful anticoagulant heparin (Cat. No. H3393).

Basic scientific research plays an important role in finding new discoveries to improve the quality of life for individuals affected with this disease. We are working diligently to provide you with the needed tools for your research endeavors.

Visit sigma.com/therapeutics for a listing of approved compounds and drug candidates available for your cardiovascular research.

 

References

  1. Johnson et al. 2006. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 130:545-52.
  2. Roger et al. 2011. Heart disease and stroke statistics–2011 update : A report from the American Heart Association. Circulation 123:e18-e209.
  3. Fuster et al. 1984. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 70:580-7.
  4. Rich et al. 1992. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76- 81.
  5. Murthy et al. 2010. New approaches to the treatment of pulmonary hypertension: from bench to bedside. Cardiol Rev. 8: 76-84.

 

Related Links